Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
Reprod Biomed Online ; 42(6): 1119-1129, 2021 06.
Article in English | MEDLINE | ID: mdl-33931367

ABSTRACT

Recent meta-analyses have shown that a hysterosalpingography (HSG) with oil-based contrast increases pregnancy rates in subfertile women. However, the frequency of complications during or after an HSG with oil-based contrast in subfertile women and/or their offspring is still unclear. This systematic review and meta-analysis, without restrictions on language, publication date or study design, was performed to fill this knowledge gap. The results show that the most frequently reported complication was intravasation of contrast, which occurred in 2.7% with the use of oil-based contrast (31 cohort studies and randomized controlled trials [RCT], 95% CI 1.7-3.8, absolute event rate 664/19,339), compared with 2.0% with the use of water-based contrast (8 cohort studies and RCT, 95% CI 1.2-3.0, absolute event rate 18/1006). In the cohort studies and RCT there were 18 women with an oil embolism (18/19,339 HSG), all without serious lasting consequences. Four cases with serious consequences of an oil embolism were described (retinal oil embolism [n = 1] and cerebral complaints [n = 3]); these reports did not describe the use of adequate fluoroscopy guidance during HSG. In conclusion, the most frequently reported complication after an HSG with oil-based contrast is intravasation occurring in 2.7%. In total four cases with serious consequences of oil embolisms in subfertile women were published.


Subject(s)
Contrast Media/adverse effects , Embolism/chemically induced , Hysterosalpingography , Iodized Oil/adverse effects , Thyroid Diseases/chemically induced , Humans
2.
Medicine (Baltimore) ; 98(48): e18095, 2019 Nov.
Article in English | MEDLINE | ID: mdl-31770228

ABSTRACT

RATIONALE: Transcatheter arterial chemoembolization (TACE) is recognized as one of the most commonly used modalities for non-surgical treatment for advanced hepatocellular carcinoma (HCC). Ectopic lipiodol embolism is an extremely rare complication of TACE. PATIENT CONCERNS: A 61-year-old man who had a 10-year history of cirrhosis caused by hepatitis B infection was diagnosed with ascites and HCC. Subsequently, the patient underwent TACE. However, he experienced persistent left upper abdominal pain, poor appetite, nausea, moderate fever and accompanied by elevation of serum and urine amylase on the 2nd and 3nd day after treatment. DIAGNOSES: The patient was diagnosed as having acute hemorrhagic necrotizing pancreatitis based on biochemical and inflammatory markers and CT findings. We deduced that the acute necrotizing pancreatitis was caused by a small branch of the left hepatic artery feeding the pancreas tail and embolizing the drug and lipiodol shunting to the tail of the pancreas. INTERVENTIONS: The patient was treated for 5 days according to the comprehensive treatment of acute necrotizing pancreatitis, by the inhibition of the secretion of pancreatic juice, relieving pain, and total parenteral nutrition and forbidding diet. The symptoms of the patient were observed to improve, and SAMS and urinary amylase (UAMS) level decreased to 143 IU/L and 254 IU/L, respectively and oral diet was permitted. OUTCOME: After a period of 2 weeks, the contrast abdominal CT showed slightly decreased fluid collection of the peri-pancreatic space. Moreover, it also showed flocculous and linear high-density shadow in the pancreatic tail, suggesting lipiodol deposition in the pancreatic tail. Subsequently, the symptoms were observed to abate, and the patient left the hospital. On the 21st day after TACE, the patient had a follow up in our outpatient department; the biochemical characteristics and inflammatory markers were observed to be normal CONCLUSION:: AP is still a rare complication after TACE. Etiology is still attributed to the occurrence of shunting and embolization drug reflux. Strategies strengthening the catheter tip that is placed as close to the distal branches of the hepatic artery for the possible careful injection of embolic materials is still the key to avoid post-TACE AP.


Subject(s)
Antineoplastic Agents/adverse effects , Chemoembolization, Therapeutic/adverse effects , Embolism/chemically induced , Ethiodized Oil/adverse effects , Pancreatitis, Acute Necrotizing/etiology , Carcinoma, Hepatocellular/therapy , Humans , Liver Neoplasms/therapy , Male , Middle Aged , Pancreas/blood supply
3.
Int J Cardiol ; 268: 113-119, 2018 Oct 01.
Article in English | MEDLINE | ID: mdl-29934230

ABSTRACT

BACKGROUND: The comparative effectiveness and safety of individual direct oral anticoagulants (DOACs) in clinical practice is largely unknown. The study objectives were to compare effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation (NVAF). METHODS: Based on nationwide registers we established a population-based historical cohort study of 12,638 new users of standard dose DOACs (apixaban 5 mg twice daily, dabigatran 150 mg twice daily and rivaroxaban 20 mg once daily) with NVAF in Denmark, July 2013 to March 2016. Patients were matched on propensity scores in a 1:1 ratio comparing apixaban vs. dabigatran (for a total of 6470 patients), apixaban vs. rivaroxaban (7352 patients), and rivaroxaban vs. dabigatran (5440 patients). Hazard ratios (HRs) for stroke or systemic embolism (effectiveness outcome) and major bleeding (safety outcome) were estimated. RESULTS: In propensity-matched comparisons of the risk of stroke or systemic embolism, the HRs were 1.27 (95% confidence interval [CI], 0.82-1.96) for apixaban vs. dabigatran, 1.25 (95% CI, 0.87-1.79) for apixaban vs. rivaroxaban, and 1.17 (95% CI, 0.69-1.96) for rivaroxaban vs. dabigatran. For the risk of major bleeding, the HRs were 0.94 (95% CI, 0.62-1.41) for apixaban vs. dabigatran, 0.88 (95% CI, 0.64-1.22) for apixaban vs. rivaroxaban, and 1.35 (95% CI, 0.91-2.00) for rivaroxaban vs. dabigatran. CONCLUSIONS: Among patients with NVAF in routine clinical practice, there were no statistically significant differences in risk of stroke or systemic embolism or major bleeding in propensity-matched comparisons between apixaban, dabigatran, and rivaroxaban used in standard doses. While analyses indicate that more than moderate differences can be excluded, smaller differences cannot be ruled out.


Subject(s)
Antithrombins/therapeutic use , Atrial Fibrillation/drug therapy , Dabigatran/therapeutic use , Factor Xa Inhibitors/therapeutic use , Pyrazoles/therapeutic use , Pyridones/therapeutic use , Rivaroxaban/therapeutic use , Aged , Aged, 80 and over , Antithrombins/adverse effects , Atrial Fibrillation/diagnosis , Cohort Studies , Dabigatran/adverse effects , Embolism/chemically induced , Factor Xa Inhibitors/adverse effects , Female , Hemorrhage/chemically induced , Humans , Male , Middle Aged , Pyrazoles/adverse effects , Pyridones/adverse effects , Registries , Rivaroxaban/adverse effects , Stroke/chemically induced , Treatment Outcome
4.
Lakartidningen ; 1122015 Nov 10.
Article in Swedish | MEDLINE | ID: mdl-26556450

ABSTRACT

When dealing with more drugs than available lumens, intravenous medications need to be co-administered in the same catheter. This type of scenario may induce therapeutic risks, such as catheter occlusion, changes in drug effect or embolization of precipitated particles. Various sources are available to provide information on compatibilities of intravenous medications. When using these sources, the applicability of the information must be assessed, comparing concentrations, diluents used and other pharmaceutical aspects. For the last three years, a group of pharmacists at Sahlgrenska University Hospital has worked on a project collecting and validating compatibility data for intravenous medications. In the future, this data will be available to more hospitals in Sweden.


Subject(s)
Administration, Intravenous/standards , Drug Incompatibility , Catheter Obstruction/etiology , Central Venous Catheters , Embolism/chemically induced , Embolism/prevention & control , Humans , Medication Errors/prevention & control , Parenteral Nutrition , Pharmacopoeias as Topic
5.
Ann Dermatol Venereol ; 140(11): 713-7, 2013 Nov.
Article in French | MEDLINE | ID: mdl-24206808

ABSTRACT

BACKGROUND: Nicolau's livedoid dermatitis is associated with drug-induced embolism in the cutaneous arterial bed, generally as a result of accidental intra-arterial injection. Herein, we report a case that is somewhat surprising because of its late onset following mesotherapy injections. CASE REPORT: A 53-year-old man, with a history solely of tendinopathy for which he underwent mesotherapy sessions, consulted for livedoid lesions of the front of the knee with central necrosis. History-taking revealed a final course of mesotherapy three weeks earlier for patellar tendinitis below the left kneecap; intradermal injection of procaine and piroxicam had been unusually and intensely painful. The remainder of the clinical examination revealed additional livedoid lesions on the outside of the left ankle as well as purpuric lesions on the pads of the toes on the left foot. Laboratory tests revealed nothing of note. Skin biopsies of the livedoid circumference of the lesion showed arteriolar emboli of an amorphous material within the dermis obliterating the arteriolar lumen. The clinical appearance of skin lesions after mesotherapy led us to a diagnosis of Nicolau livedoid dermatitis. DISCUSSION: Nicolau dermatitis is a rare skin complication described as occurring mainly as a result of intramuscular injections. The reported case is special because it comprises Nicolau dermatitis arising out of a session of mesotherapy employing an intradermal injection. However, there are only very few cases in which subcutaneous injections have induced Nicolau dermatitis. The pathophysiology is not well known, but several mechanisms are involved: arterial ischaemia by vasospasm or thrombosis. In this case, the semiotic appearance of the lesions and histological analysis militate in favour of accidental injection of a skin product into an arteriole, resulting in obliteration of the latter. Mesotherapy can induce Nicolau dermatitis.


Subject(s)
Anesthetics, Local/adverse effects , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Drug Eruptions/etiology , Embolism/chemically induced , Knee/blood supply , Mesotherapy/adverse effects , Skin Diseases, Vascular/chemically induced , Anesthetics, Local/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Arterioles/pathology , Drug Eruptions/pathology , Embolism/pathology , Humans , Injections, Intradermal/adverse effects , Male , Middle Aged , Necrosis , Patellar Ligament , Piroxicam/administration & dosage , Piroxicam/adverse effects , Procaine/administration & dosage , Procaine/adverse effects , Skin Diseases, Vascular/pathology , Tendinopathy/therapy
6.
Vasa ; 39(3): 271-3, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20799166

ABSTRACT

After cisplatin / 5-fluorouracil chemotherapy for nasopharyngeal carcinoma, an 18-year female patient developed aortobifemoral embolism. Besides chemotherapy, additional risk factors for arterial thromboembolic events were smoking, contraceptive medication and adjuvant antiemetic treatment with dexamethasone. Thrombophilia screening was negative. Thromboembolic complications during or after cisplatin have been reported in a frequency of 17.6 % in lung cancer patients, and in 8.4 % of patients with germ cell tumors. The incidence of arterial thromboembolic events was 9.3 % and 1.7 %, respectively. The pathogenesis of cisplatin induced thromboembolism is thought to be caused by endothelial damage leading to endothelial cell dysfunction, increased von Willebrand factor plasma levels, and hypomagnesaemia.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Aortic Diseases/chemically induced , Arterial Occlusive Diseases/chemically induced , Carcinoma/drug therapy , Embolism/chemically induced , Femoral Artery , Ischemia/chemically induced , Nasopharyngeal Neoplasms/drug therapy , Adolescent , Antiemetics/adverse effects , Aortic Diseases/diagnostic imaging , Aortic Diseases/therapy , Arterial Occlusive Diseases/diagnostic imaging , Arterial Occlusive Diseases/therapy , Cisplatin/administration & dosage , Contraceptive Agents, Female/adverse effects , Embolectomy , Embolism/diagnostic imaging , Embolism/therapy , Female , Femoral Artery/diagnostic imaging , Fluorouracil/administration & dosage , Humans , Ischemia/diagnostic imaging , Ischemia/therapy , Risk Factors , Smoking/adverse effects , Tomography, X-Ray Computed , Treatment Outcome
9.
Arch Pathol Lab Med ; 107(10): 548-51, 1983 Oct.
Article in English | MEDLINE | ID: mdl-6351803

ABSTRACT

Fatal generalized barium sulfate (BaSO4) embolization followed erroneous vaginal insertion of the enema tip intended for colon examination. Light microscopy revealed the presence of swollen, granular reticuloendothelial cells in most visceral organs such as lung, liver, spleen, bone marrow, kidney, and brain. Transmission electron microscopy showed the reticuloendothelial cells loaded with uniformly electron-dense granules of various sizes. Scanning electron microscopy equipped with an energy-dispersive x-ray analyzer confirmed the BaSO4 composition of these granules when unstained paraffin sections of different organs mounted on glass slides without coverslips were examined. The use of the technique of x-ray microanalysis is recommended when absolute identification of inorganic material in human organs is needed. The technique can be used directly on routine paraffin-embedded material mounted on glass slides as well as with material expressly prepared.


Subject(s)
Barium Sulfate/adverse effects , Embolism/chemically induced , Enema/adverse effects , Vagina , Age Factors , Aged , Barium Sulfate/analysis , Electron Probe Microanalysis , Female , Humans , Kupffer Cells/pathology , Lung/analysis , Lung/pathology , Microscopy, Electron , Spleen/analysis , Spleen/pathology , Vagina/blood supply , Vagina/pathology
10.
Lymphology ; 15(2): 70-3, 1982 Jun.
Article in English | MEDLINE | ID: mdl-6287122

ABSTRACT

The authors report on 12 personal observations of lymphoportal fistulas, which represented 0.24% of their series of lymphographies. This rare complication of lymphography has no clinical or biological liver manifestations. Review of 71 cases in the literature confirmed that hepatic oil embolization only occurs when there are lymphatic masses, with or without associated thrombosis of the inferior vena cava.


Subject(s)
Embolism/chemically induced , Iodized Oil/adverse effects , Liver/diagnostic imaging , Adult , Aged , Embolism/complications , Embolism/diagnostic imaging , Female , Fistula/complications , Fistula/diagnostic imaging , Humans , Lymphatic Diseases/complications , Lymphatic Diseases/diagnostic imaging , Lymphography/adverse effects , Male , Middle Aged , Neoplasms/complications , Neoplasms/diagnosis , Portal Vein
15.
SELECTION OF CITATIONS
SEARCH DETAIL